1. Home
  2. AMRX vs MIRM Comparison

AMRX vs MIRM Comparison

Compare AMRX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

SELL

Current Price

$21.23

Market Cap

6.4B

Sector

Health Care

ML Signal

SELL

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

SELL

Current Price

$91.51

Market Cap

7.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AMRX
MIRM
Founded
2002
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
7.2B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
AMRX
MIRM
Price
$21.23
$91.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
12
Target Price
$24.29
★ $157.71
AVG Volume (30 Days)
★ 3.5M
559.1K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 157.89
74.59
EPS
★ 0.29
N/A
Revenue
N/A
★ $19,138,000.00
Revenue This Year
$6.38
$37.65
Revenue Next Year
$9.21
$21.04
P/E Ratio
$73.78
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.39
$63.23
52 Week High
$22.07
$130.00

Technical Indicators

Market Signals
Indicator
AMRX
MIRM
Relative Strength Index (RSI) 57.02 56.52
Support Level $18.90 $87.38
Resistance Level $21.21 $98.34
Average True Range (ATR) 0.86 4.15
MACD 0.04 0.73
Stochastic Oscillator 71.96 60.16

Price Performance

Historical Comparison
AMRX
MIRM

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: